Albireo, An Ipsen Company
Clinical trials sponsored by Albireo, An Ipsen Company, explained in plain language.
-
Hope for kids with rare liver disease: 2-Year drug trial aims to prevent transplants
Disease control ENROLLING_BY_INVITATIONThis study is a 2-year follow-up to see if a drug called odevixibat can help children with biliary atresia live longer without needing a liver transplant. It will track about 180 children who were in a previous study to measure the drug's long-term safety and its effect on liver …
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Race against time: can new drug save Kids' livers?
Disease control OngoingThis study is testing whether a medicine called odevixibat can help children with biliary atresia who have had Kasai surgery. The main goal is to see if the drug can delay or prevent the need for a liver transplant and reduce harmful bile acids in the blood. About 254 children wi…
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC